Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman

3 Visningar
administrator
administrator
07/30/23

A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd

  • Kategori

Visa mer

0 Kommentarer Sortera efter

Inga kommentarer hittades

Facebook-kommentarer

Strax